Targeting of radionuclides with antibodies, or radioimmunotherapy, has been an active field
of research spanning nearly 50 years, evolving with advancing technologies in molecular …

Since the FDA approval of the first therapeutic antibody 35 years ago, antibody-based
products have gained prominence in the pharmaceutical market. Building on the early …

The cure of cancer is still a formidable challenge in medical science. Long-known modalities
including surgery, chemotherapy and radiotherapy are successful in a number of cases; …

Abstract “Radiotheranostics” is a term used in nuclear medicine to refer to the use of
radioisotope (RI)-labeled agents to perform simultaneous imaging and therapy of a target …

Introduction: The generation of cytotoxic drugs, selectively within tumours, from non-toxic
prodrugs by targeted enzymes provides a powerful system for cancer therapy. In the form of …

Colorectal cancer (CRC) is the fourth most common cause of cancer and mortality worldwide
and is the third most common cancer in men and women. Surgery, radiotherapy, and …

Monoclonal antibodies (mAbs) are included among the treatment options for advanced
colorectal cancer (CRC). However, while these mAbs effectively target cancer cells, they …

Tagging of RNases, such as the ribotoxin α-sarcin, with the variable domains of antibodies
directed to surface antigens that are selectively expressed on tumor cells endows cellular …

Advances in biomolecular technology have allowed the development of genetically fused
antibody–enzymes. Antibody–enzyme fusion proteins have been used to target tumors for …

Immunotoxins are chimeric proteins composed of an antibody domain that specifically
directs the action of the toxic domain, resulting in the death of the targeted cells. Over recent …